In 2017, 25.7 percent of all angel capital group deals went to a founding team with at least one female founder, up from 17.0 percent in 2016, according to the Angel Resource Institute’s (ARI) HALO Report: 2017. The report also found a sizeable increase in the number of deals made for companies that included at least one minority female founder – 5.5 percent in 2017 (1.0 percent in 2016).
San Diego. New Haven. Boston.
Besides cities that make for a nice waterside vacation, these destinations seem to have figured out the complex, yet irresistible, world of bioscience investment.
The Biohealth Capital Region–DC, Maryland and Virginia – plans to be a top 3 biohealth hub in the US by 2023. What will it take to get there?
The Biohealth Capital Region is already a top 5 location as ranked by NIH and venture capital funding, patents, lab space, and jobs. The 1,100 participants at this week’s 2018 Biohealth Capital Region Forum agreed on the area’s strengths: a highly educated and diverse workforce, leading universities and research institutions, strong healthcare organizations, hundreds of companies, and broad-based policy commitment to the biohealth industry.
Competition held during 2018 BioHealth Capital Region Forum
Wilson Sonsini’s Charlie Andres and BHI’s Rich Bendis present the team from Galen Robotics
their award for winning the 2018 Crab Trap competition
ROCKVILLE, MARYLAND, April 26, 2018 – Galen Robotics, a Johns Hopkins University spinout, was chosen from five finalists as the company with the most commercial potential by judges at the 3rd Annual Crab Trap Competition. This year’s judges included industry leaders Amgen’s Bethany Mancilla, AstraZeneca’s Shaun Grady, Blu Venture’s Dr. Paul Silber, J.P. Morgan’s John T. Rubin, New Enterprise Associates’ Sara Nayeem, Roche’s Robert Silverman, and Sands Capital Ventures’ Stephen Zachary. They were impressed with a presentation by Lead Hardware Engineer, Yunus Sevimli, on Galen Robotics’ low-cost, compact, and intuitive to use novel microsurgical robotic platform designed to assist surgeons with minimally-invasive applications in otolaryngology, neurosurgery and similar critical fields. Galen Robotics is the third Johns Hopkins University spinout to win this competition following LifeSprout (2017) and Sonavex (2016).
Strong presentations also were made by the other finalists–AlgometRx, Cellth Systems, Renalert, and Reveragen Biopharma—whose technologies originated at Children’s National Medical Center, the University of Maryland, and Johns Hopkins University.
Are you involved in the fight against drug resistant bacteria? Between June 1 and June 8th, organizations seeking funding to advance antimicrobial technologies (diagnostics, therapeutics or devices) will have the opportunity to submit Expressions of Interest (EOI) to CARB-X. CARB-X is dedicated to accelerating global antibacterial innovation through targeted funding of focused projects. Only technologies specifically focused on the Pathogens outlined in the CARB-X 2018 Funding Round 2 Scope will be considered. Now is the time to beginning preparing your EOI. More information is available on the CARB-X website: http://www.carb-x.org/application
Is your employee compensation package competitive?
Help us help you. Complete the 2018 BHCR Industry Compensation Survey by June 1, 2018 to receive an anonymized summary of salaries and benefits specific to positions in biohealth and to this region. A pdf version of the survey is available here or you can use the online version of the survey to complete your information. All company specific information will be kept confidential. This survey is a joint project among BioHealth Innovation, WorkSource Montgomery, and UMBC-Shady Grove’s Industrial Organizational Pyschology Program. If you or your Human Resources colleagues have any questions about the survey, please contact BHI@BioHealthInnovation.org.
MaxCyte, the global cell-based medicines and life sciences company, announced today that it has appointed Claudio Dansky Ullmann, MD, a 25+-year expert in clinical oncology and pharmaceutical research, as its Chief Medical Officer (CMO). In his new role, Dr. Dansky Ullmann is responsible for overseeing clinical development of MaxCyte’s CARMA™ drug development program as the company’s first candidate, MCY-M11, is expected to enter the clinic this year.
Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, today announced the close of a $60 million USD Series B funding round. The financing will accelerate growth of Corvidia’s ongoing clinical programs, expand scientific and market access capabilities and explore new treatment areas.
Patients dealing with hypotension, or dangerously low blood pressure, can now be treated with a drug initially developed by George Washington University researcher Lakhmir Chawla from the School of Medicine and Health Sciences and the GW Medical Faculty Associates.
Towson University celebrated the start of construction on the new science complex with a groundbreaking ceremony on the top floor of the Glen Garage April 17.
Construction for the new science complex began in fall 2017, but the ceremony marked the University officially breaking ground on the project.
